This inventor holds 11 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Regents of the University of Minnesota. Active years: 2016-2025.
Location History:
- Saint Paul, MN (US) (2016)
- New Brighton, MN (US) (2017 - 2018)
- Spring Park, MN (US) (2019)
- Minneapolis, MN (US) (2017 - 2023)
Company Filing History:
Years Active: 2016-2025
Title: Michael R Olin: Innovator in Cancer Immunotherapy
Introduction
Michael R Olin is a prominent inventor based in New Brighton, MN (US). He has made significant contributions to the field of cancer immunotherapy, holding a total of 11 patents. His work focuses on innovative methods to enhance the efficacy of cancer treatments, particularly through the modulation of immune responses.
Latest Patents
Among his latest patents, Olin has developed the "CD200AR ligands for cancer immunotherapy." This invention provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L). Additionally, it offers a method to enhance the efficacy of a tumor lysate vaccine in mammals by administering the CD200AR-L prior to the vaccine. Another notable patent is "CD200 inhibitors and methods of use thereof," which includes compositions comprising at least one CD200 inhibitor. This method aims to reverse or modulate immune suppression in patients with diseases arising from abnormal cell growth.
Career Highlights
Michael R Olin is affiliated with the Regents of the University of Minnesota, where he continues to advance his research in immunotherapy. His innovative approaches have the potential to significantly impact cancer treatment protocols.
Collaborations
Olin has collaborated with esteemed colleagues such as John R Ohlfest and Walter C Low, contributing to a rich environment of research and development in the field of cancer immunotherapy.
Conclusion
Michael R Olin's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. His patents and research efforts are paving the way for new therapeutic strategies that could improve patient outcomes.